Alvotech (NASDAQ:ALVO) Trading Down 5.1% - Here's What Happened

Key Points

• Shares fell 5.1% to about $3.35 on Monday, with ~510,264 shares traded—slightly below the stock's average daily volume and well under its 50‑day ($4.53) and 200‑day ($5.84) moving averages.
• Analysts are mixed: the consensus rating is Hold with a $8.60 average target, while individual price targets range from $5 (Barclays, underweight) to $10 (Morgan Stanley) and ratings span Buy/Hold/Sell.
• Alvotech reported a quarterly EPS miss (‑$0.37 vs. $0.13 expected) but revenue beat ($173.2M vs. $162.2M); the company has a ~$1.0B market cap and analysts project a negative full‑year EPS (~‑0.07).

Shares of Alvotech (NASDAQ:ALVO - Get Free Report) were down 5.1% during trading on Monday . The stock traded as low as $3.33 and last traded at $3.35. Approximately 510,264 shares traded hands during mid-day trading, a decline of 3% from the average daily volume of 527,896 shares. The stock had previously closed at $3.53.

Wall Street Analyst Weigh In

Several brokerages have recently commented on ALVO. Morgan Stanley set a $10.00 price target on shares of Alvotech in a research note on Wednesday, December 3rd. Barclays started coverage on shares of Alvotech in a report on Monday, December 8th. They issued an "underweight" rating and a $5.00 price objective for the company. Weiss Ratings reissued a "sell (e+)" rating on shares of Alvotech in a research report on Wednesday, January 21st. Finally, Zacks Research raised Alvotech from a "strong sell" rating to a "hold" rating in a research report on Thursday. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $8.60.

Alvotech Price Performance

The company has a market cap of $1.00 billion, a price-to-earnings ratio of 33.27 and a beta of 0.16. The firm has a fifty day simple moving average of $4.53 and a 200 day simple moving average of $5.84.

Alvotech (NASDAQ:ALVO - Get Free Report) last issued its quarterly earnings data on Wednesday, March 18th. The company reported ($0.37) earnings per share for the quarter, missing analysts' consensus estimates of $0.13 by ($0.50). The firm had revenue of $173.20 million during the quarter, compared to analyst estimates of $162.20 million. Alvotech had a negative return on equity of 12.84% and a net margin of 4.74%. Analysts expect that Alvotech will post -0.07 earnings per share for the current year.

Institutional Investors Weigh In On Alvotech

Several hedge funds and other institutional investors have recently made changes to their positions in ALVO. Norges Bank bought a new stake in shares of Alvotech in the second quarter valued at approximately $1,656,000. Legal & General Group Plc increased its position in Alvotech by 17.0% during the second quarter. Legal & General Group Plc now owns 657,742 shares of the company's stock worth $6,028,000 after acquiring an additional 95,331 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in Alvotech by 25.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,211 shares of the company's stock worth $78,000 after acquiring an additional 3,110 shares during the period. Tempus Wealth Planning LLC raised its stake in Alvotech by 59.4% during the 4th quarter. Tempus Wealth Planning LLC now owns 53,880 shares of the company's stock valued at $276,000 after purchasing an additional 20,074 shares during the last quarter. Finally, Ulland Investment Advisors LLC boosted its holdings in Alvotech by 544.4% in the 4th quarter. Ulland Investment Advisors LLC now owns 72,500 shares of the company's stock valued at $372,000 after purchasing an additional 61,250 shares during the period.

About Alvotech

Alvotech NASDAQ: ALVO is a global biopharmaceutical company specializing in the development, manufacturing and commercialization of biosimilar medicines. The company focuses on creating high‐quality, cost‐effective alternatives to established biologic therapies in areas such as immunology, oncology and other specialty care fields. By leveraging in‐house research and a vertically integrated manufacturing platform, Alvotech aims to bring approved biosimilars to market more rapidly and with greater cost efficiency than many traditional biosimilar developers.

Since its founding in 2013, Alvotech has built a diversified pipeline of monoclonal antibody biosimilars, targeting blockbuster reference products including adalimumab (originally branded Humira), bevacizumab (Avastin) and ustekinumab (Stelara).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.